Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: Prospective analysis of 197 patients with chronic hepatitis C viral infection

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 6-7, 2007, Pages 566-572

  Fontanges, Thierry ^a   Beorchia, Sylvain ^a   Douvin, Catherine ^a   Delassalle, Patrick ^a   Combis, Jean Marc ^b   Hanslik, Bertrand ^a   Jacques, Jean Paul ^a   Filoche, Bernard ^a   Desmorat, Hervé ^c   Chandelier, Catherine ^a   Ouzan, Denis ^a  

^a Clinique Ambroise Paré ^*  (France)

^b Reseau Hepatite C 31   (France)

^c Polyclinique du Parc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CONSULTATION; COUGHING; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; GASTROENTEROLOGY; GENOTYPE; HEADACHE; HEPATITIS C; HEPATOGASTROENTEROLOGY; HUMAN; INSOMNIA; IRRITABILITY; LOBAR PNEUMONIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; OUTPATIENT; PANIC; PATIENT COMPLIANCE; PERICARDITIS; PERIPHERAL NEUROPATHY; POPULATION; PREVALENCE; PROSPECTIVE STUDY; PRURITUS; SEIZURE; SIDE EFFECT; SUICIDE ATTEMPT; THROMBOCYTOPENIA; VIROLOGY; VIRUS INFECTION;

EID: 34447643590     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)89432-2     Document Type: Article

References (22)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
2. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
3. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in non cirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8.
4. ANAES. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002;26(Suppl 2):B303-B320.
5. Aspinall RJ, Pockros PJ. The management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther 2004;20:917-29.
6. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:237-44.
7. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-12.
8. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000;18:107-16.
9. Strinko JM, Di Bisceglie AM, Hoffmann JA. A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: does nursing play a role? Issues Ment Health Nurs 2004;25:715-22.
10. Kraus MR, Schafer A, Al Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005;12:96-100.
11. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9.
12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
13. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
14. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
15. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
16. Dahari H, Homburger Y, Verheij-Hart E, Zeuzem S. Effects of peg-IFN-alfa2a (40kD) dose reduction, ribavirin dose reduction and ribavirin interruption on hepatitis C viral kinetics and its correlation to SVR in the DITTO-HCV study (abstract). Hepatology 2004;40:324A.
17. Reddy KR, Fried MW, Shiffman M, Hadziyannis SJ, Sette H, Morgan TR, et al. The influence of cumulative exposure to combination peginterferon alfa-2a (40kD) (Pegasys) and ribavirin on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C (abstract). J Hepatol 2004;40:149.
18. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005;41:275-9.
19. Lunel-Fabiani F, Fouchard-Hubert I, Gergely AE. [Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C]. Pathol Biol 2003;51:520-4.
20. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004;71(Suppl 3):S17-S21.
21. Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004;40:1450-8.
22. Sanchez-Tapias JM, Diago M, Escartin P, Moreno R, Romero-Gomez M, Barcena R, et al. Sustained virological response after prolonged treatment with Peginterferon alfa-2a (40kD) (PEGASYS) and ribavirin (COPEGUS) in treatment-naive patients with chronic hepatitis C and detectable HCV-RNA after week 4 of therapy: Tera Vic-4 study (abstract). J Hepatol 2004;40:150.